A Prospective Study of Plasma Vitamin D Metabolites, Vitamin D Receptor Polymorphisms, and Prostate Cancer
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Vitamin D insufficiency is a common public health problem nationwide. Circulating 25-hydroxyvitamin D3 (25[OH]D), the most commonly used index of vitamin D status, is converted to the active hormone 1,25 dihydroxyvitamin D3 (1,25[OH]2D), which, operating through the vitamin D receptor (VDR), inhibits in vitro cell proliferation, induces differentiation and apoptosis, and may protect against prostate cancer. Despite intriguing results from laboratory studies, previous epidemiological studies showed inconsistent associations of circulating levels of 25(OH)D, 1,25(OH)2D, and several VDR polymorphisms with prostate cancer risk. Few studies have explored the joint association of circulating vitamin D levels with VDR polymorphisms. METHODS AND FINDINGS: During 18 y of follow-up of 14,916 men initially free of diagnosed cancer, we identified 1,066 men with incident prostate cancer (including 496 with aggressive disease, defined as stage C or D, Gleason 7-10, metastatic, and fatal prostate cancer) and 1,618 cancer-free, age- and smoking-matched control participants in the Physicians' Health Study. We examined the associations of prediagnostic plasma levels of 25(OH)D and 1,25(OH)2D, individually and jointly, with total and aggressive disease, and explored whether relations between vitamin D metabolites and prostate cancer were modified by the functional VDR FokI polymorphism, using conditional logistic regression. Among these US physicians, the median plasma 25(OH)D levels were 25 ng/ml in the blood samples collected during the winter or spring and 32 ng/ml in samples collected during the summer or fall. Nearly 13% (summer/fall) to 36% (winter/spring) of the control participants were deficient in 25(OH)D (<20 ng/ml) and 51% (summer/fall) and 77% (winter/spring) had insufficient plasma 25(OH)D levels (<32 ng/ml). Plasma levels of 1,25(OH)2D did not vary by season. Men whose levels for both 25(OH)D and 1,25(OH)2D were below (versus above) the median had a significantly increased risk of aggressive prostate cancer (odds ratio [OR] = 2.1, 95% confidence interval [CI] 1.2-3.4), although the interaction between the two vitamin D metabolites was not statistically significant (pinteraction = 0.23). We observed a significant interaction between circulating 25(OH)D levels and the VDR FokI genotype (pinteraction < 0.05). Compared with those with plasma 25(OH)D levels above the median and with the FokI FF or Ff genotype, men who had low 25(OH)D levels and the less functional FokI ff genotype had increased risks of total (OR = 1.9, 95% CI 1.1-3.3) and aggressive prostate cancer (OR = 2.5, 95% CI 1.1-5.8). Among men with plasma 25(OH)D levels above the median, the ff genotype was no longer associated with risk. Conversely, among men with the ff genotype, high plasma 25(OH)D level (above versus below the median) was related to significant 60% approximately 70% lower risks of total and aggressive prostate cancer. CONCLUSIONS: Our data suggest that a large proportion of the US men had suboptimal vitamin D status (especially during the winter/spring season), and both 25(OH)D and 1,25(OH)2D may play an important role in preventing prostate cancer progression. Moreover, vitamin D status, measured by 25(OH)D in plasma, interacts with the VDR FokI polymorphism and modifies prostate cancer risk. Men with the less functional FokI ff genotype (14% in the European-descent population of this cohort) are more susceptible to this cancer in the presence of low 25(OH)D status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Final Report on the Aspirin Component of the Ongoing Physicians' Health Study
Steering Committee of the Physicians' Health Study Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198907203210301 · Cited by 2,264
Prediction of bone density from vitamin D receptor alleles
Morrison, N. A., Qi, J. C., Tokita, A., Kelly, P. J., Crofts, L., Nguyen, T. V., Sambrook, P. N., & Eisman, J. A. (1994) · Nature · doi:10.1038/367284a0 · Cited by 1,919
Genetics and biology of vitamin D receptor polymorphisms
Uitterlinden, A. G., Fang, Y., van Meurs, J. B. J., Pols, H. A. P., & van Leeuwen, J. P. T. M. (2004) · Gene · doi:10.1016/j.gene.2004.05.014 · Cited by 1,539
Hollis, B. W. (2005) · The Journal of Nutrition · doi:10.1093/jn/135.2.317 · Cited by 1,162
Arai, H., Miyamoto, K.-I., Taketani, Y., Yamamoto, H., Iemori, Y., Morita, K., Tonai, T., Nishisho, T., Mori, S., & Takeda, E. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.6.915 · Cited by 651
Hanchette, C. L., & Schwartz, G. G. (1992) · Cancer · doi:10.1002/1097-0142(19921215)70:12<2861::aid-cncr2820701224>3.0.co;2-g · Cited by 645
Localized scleroderma-response to 1,25-dihydroxyvitamin D3
HUMBERT, P. G., DUPOND, J. L., ROCHEFORT, A., VASSELET, R., LUCAS, A., LAURENT, R., & AGACHE, P. (1990) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1990.tb02127.x · Cited by 612
Benefits and requirements of vitamin D for optimal health: a review.
Grant, W. B., & Holick, M. F. (2005) · PubMed · Cited by 610
Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis).
Schwartz, G. G., & Hulka, B. S. (1990) · PubMed · Cited by 585
Assay Variation Confounds the Diagnosis of Hypovitaminosis D: A Call for Standardization
Binkley, N., Krueger, D., Cowgill, C. S., Plum, L., Lake, E., Hansen, K. E., DeLuca, H. F., & Drezner, M. K. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031979 · Cited by 577
Cited by
Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice
Bouillon, R., Carmeliet, G., Verlinden, L., van Etten, E., Verstuyf, A., Luderer, H. F., Lieben, L., Mathieu, C., & Demay, M. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0004 · Cited by 1,783
The Epidemiology of Prostate Cancer
Pernar, C. H., Ebot, E. M., Wilson, K. M., & Mucci, L. A. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030361 · Cited by 773
Self-citationGandini, S., Boniol, M., Haukka, J., Byrnes, G., Cox, B., Sneyd, M. J., Mullie, P., & Autier, P. (2011) · International Journal of Cancer · doi:10.1002/ijc.25439 · Cited by 499
Vitamin D for Cancer Prevention: Global Perspective
Garland, C. F., Gorham, E. D., Mohr, S. B., & Garland, F. C. (2009) · Annals of Epidemiology · doi:10.1016/j.annepidem.2009.03.021 · Cited by 438
Chung, M., Lee, J., Terasawa, T., Lau, J., & Trikalinos, T. A. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-12-201112200-00005 · Cited by 415
Prevalence of Vitamin D Insufficiency in Patients With Parkinson Disease and Alzheimer Disease
Evatt, M. L., DeLong, M. R., Khazai, N., Rosen, A., Triche, S., & Tangpricha, V. (2008) · Archives of Neurology · doi:10.1001/archneur.65.10.1348 · Cited by 378
Serum Vitamin D Concentration and Prostate Cancer Risk: A Nested Case-Control Study
Ahn, J., Peters, U., Albanes, D., Purdue, M. P., Abnet, C. C., Chatterjee, N., Horst, R. L., Hollis, B. W., Huang, W.-Y., Shikany, J. M., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn152 · Cited by 282
Mollinedo, F., & Gajate, C. (2020) · Journal of Lipid Research · doi:10.1194/jlr.tr119000439 · Cited by 279
Anticancer steroids: linking natural and semi-synthetic compounds
Salvador, J. A. R., Carvalho, J. F. S., Neves, M. A. C., Silvestre, S. M., Leitão, A. J., Silva, M. M. C., & Sá e Melo, M. L. (2013) · Nat. Prod. Rep. · doi:10.1039/c2np20082a · Cited by 276
Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk
Raimondi, S., Johansson, H., Maisonneuve, P., & Gandini, S. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp103 · Cited by 265
Ultraviolet Radiations: Skin Defense-Damage Mechanism
Mohania, D., Chandel, S., Kumar, P., Verma, V., Digvijay, K., Tripathi, D., Choudhury, K., Mitten, S. K., & Shah, D. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-56017-5_7 · Cited by 262
Chan, S.-H., Stoddard, B. L., & Xu, S.-Y. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq742 · Cited by 217
“From routine DNA cloning to detection of DNA sequence polymorphism (1,2) to CpG methylation profiling (3), analyses of gene expression in serial analysis of gene expression (SAGE) (4,5) and most recently sample preparation for high-throughput DNA sequencing (6,7), molecular biologists need REases.”
Background25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men
Slinin, Y., Paudel, M. L., Taylor, B. C., Fink, H. A., Ishani, A., Canales, M. T., Yaffe, K., Barrett-Connor, E., Orwoll, E. S., Shikany, J. M., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c7197b · Cited by 193
Metadata
- Authors
- Li, H., Stampfer, M. J., Hollis, J. B. W., Mucci, L. A., Gaziano, J. M., Hunter, D., Giovannucci, E. L., & Ma, J.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-03-20
- Volume
- 4
- Issue
- 3
- Pages
- e103
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2113143740
- Cited by
- 290
- References
- 41
- FWCI
- 18.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.